Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance.